Matches in SemOpenAlex for { <https://semopenalex.org/work/W1849277508> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W1849277508 endingPage "8" @default.
- W1849277508 startingPage "541" @default.
- W1849277508 abstract "Abecarnil (ZK 112119; isopropyl-6-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate), a novel beta-carboline with high affinity for central benzodiazepine (BZ) receptors, has been shown recently to be a potent anxiolytic and anticonvulsant in animal models whereas lacking ataxia-producing effects, a profile typical for a partial agonist at BZ receptors. In the present study abecarnil was tested in dogs after acute and chronic administration. Pharmacokinetic studies showed that abecarnil was eliminated rapidly after i.v. or p.o. administration, but elimination was delayed substantially after s.c. injection. After i.v. injection, the drug penetrated rapidly into the cerebrospinal fluid, but maximum concentrations reached in cerebrospinal fluid were only 6 to 8% of those in plasma. Anticonvulsant potency of abecarnil in dogs was studied by means of seizures induced by i.v. infusion of pentylenetetrazol. After i.v. administration of single doses, abecarnil was about half as potent as diazepam, dose-dependently increasing the pentylenetetrazol threshold by doses of 0.1-1 mg/kg. In contrast to diazepam, most dogs injected with abecarnil at anticonvulsant doses showed no ataxia. During chronic s.c. administration of abecarnil for 6 weeks, the anticonvulsant efficacy of the drug increased markedly during the first week(s) of treatment, possibly indicating drug accumulation in the brain. During the subsequent weeks of treatment, there was a slight reduction in anticonvulsant potency. No withdrawal symptoms were observed after cessation of the 6-week administration period. Furthermore, injection of the BZ antagonist Ro 15-1788 (flumazenil), 1 mg/kg i.v., after 5 weeks of treatment did not precipitate withdrawal symptoms except slight tremor in two of seven dogs studied.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
- W1849277508 created "2016-06-24" @default.
- W1849277508 creator A5009452576 @default.
- W1849277508 creator A5018364649 @default.
- W1849277508 creator A5055852211 @default.
- W1849277508 creator A5081378359 @default.
- W1849277508 creator A5086089526 @default.
- W1849277508 date "1990-11-01" @default.
- W1849277508 modified "2023-10-12" @default.
- W1849277508 title "Pharmacokinetics, anticonvulsant efficacy and adverse effects of the beta-carboline abecarnil, a novel ligand for benzodiazepine receptors, after acute and chronic administration in dogs." @default.
- W1849277508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1978730" @default.
- W1849277508 hasPublicationYear "1990" @default.
- W1849277508 type Work @default.
- W1849277508 sameAs 1849277508 @default.
- W1849277508 citedByCount "13" @default.
- W1849277508 countsByYear W18492775082022 @default.
- W1849277508 crossrefType "journal-article" @default.
- W1849277508 hasAuthorship W1849277508A5009452576 @default.
- W1849277508 hasAuthorship W1849277508A5018364649 @default.
- W1849277508 hasAuthorship W1849277508A5055852211 @default.
- W1849277508 hasAuthorship W1849277508A5081378359 @default.
- W1849277508 hasAuthorship W1849277508A5086089526 @default.
- W1849277508 hasConcept C118552586 @default.
- W1849277508 hasConcept C168258287 @default.
- W1849277508 hasConcept C170493617 @default.
- W1849277508 hasConcept C185592680 @default.
- W1849277508 hasConcept C202751555 @default.
- W1849277508 hasConcept C2775858608 @default.
- W1849277508 hasConcept C2776175493 @default.
- W1849277508 hasConcept C2776819090 @default.
- W1849277508 hasConcept C2777010014 @default.
- W1849277508 hasConcept C2778173252 @default.
- W1849277508 hasConcept C2778186239 @default.
- W1849277508 hasConcept C2778409475 @default.
- W1849277508 hasConcept C55493867 @default.
- W1849277508 hasConcept C57992300 @default.
- W1849277508 hasConcept C71924100 @default.
- W1849277508 hasConcept C98274493 @default.
- W1849277508 hasConceptScore W1849277508C118552586 @default.
- W1849277508 hasConceptScore W1849277508C168258287 @default.
- W1849277508 hasConceptScore W1849277508C170493617 @default.
- W1849277508 hasConceptScore W1849277508C185592680 @default.
- W1849277508 hasConceptScore W1849277508C202751555 @default.
- W1849277508 hasConceptScore W1849277508C2775858608 @default.
- W1849277508 hasConceptScore W1849277508C2776175493 @default.
- W1849277508 hasConceptScore W1849277508C2776819090 @default.
- W1849277508 hasConceptScore W1849277508C2777010014 @default.
- W1849277508 hasConceptScore W1849277508C2778173252 @default.
- W1849277508 hasConceptScore W1849277508C2778186239 @default.
- W1849277508 hasConceptScore W1849277508C2778409475 @default.
- W1849277508 hasConceptScore W1849277508C55493867 @default.
- W1849277508 hasConceptScore W1849277508C57992300 @default.
- W1849277508 hasConceptScore W1849277508C71924100 @default.
- W1849277508 hasConceptScore W1849277508C98274493 @default.
- W1849277508 hasIssue "2" @default.
- W1849277508 hasLocation W18492775081 @default.
- W1849277508 hasOpenAccess W1849277508 @default.
- W1849277508 hasPrimaryLocation W18492775081 @default.
- W1849277508 hasRelatedWork W157685416 @default.
- W1849277508 hasRelatedWork W1849277508 @default.
- W1849277508 hasRelatedWork W1972522228 @default.
- W1849277508 hasRelatedWork W2007943279 @default.
- W1849277508 hasRelatedWork W2016252914 @default.
- W1849277508 hasRelatedWork W2022005638 @default.
- W1849277508 hasRelatedWork W2024244810 @default.
- W1849277508 hasRelatedWork W2059314981 @default.
- W1849277508 hasRelatedWork W2255203930 @default.
- W1849277508 hasRelatedWork W2257697159 @default.
- W1849277508 hasVolume "255" @default.
- W1849277508 isParatext "false" @default.
- W1849277508 isRetracted "false" @default.
- W1849277508 magId "1849277508" @default.
- W1849277508 workType "article" @default.